Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025)

Universe Pharmaceuticals' Current Deferred Revenue history spans 1 years, with the latest figure at $40.7 million for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $40.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $40.7 million, a N/A change, with the full-year FY2025 number at $40.7 million, changed N/A from a year prior.
  • Current Deferred Revenue hit $40.7 million in Q3 2025 for Universe Pharmaceuticals.
  • Over the last five years, Current Deferred Revenue for UPC hit a ceiling of $40.7 million in Q3 2025 and a floor of $40.7 million in Q3 2025.